Alanyl-tRNA synthetase domain-containing protein 1–PTGES3L readthrough protein (PTGES3L-AARSD1)

The PTGES3L-AARSD1 readthrough loci generate a fusion protein encoded by overlapping transcription of the PTGES3L and AARSD1 genes on chromosome 17. This fusion protein participates in aminoacyl-tRNA editing, specifically by correcting incorrectly charged tRNA(Ala), which is an important function for maintaining translational fidelity[3][4]. There is suggestive evidence that PTGES3L-AARSD1 may be involved in cellular stress responses—particularly in modulating transcription following oxidative DNA damage, potentially influencing immune gene activation[1]. However, PTGES3L-AARSD1 is not currently established as a therapeutic target in drug development. The gene has been associated with the hereditary motor neuron diseases, but its exact mechanistic contribution remains unclear[3][4]. No approved drugs target PTGES3L-AARSD1, and there are no established concerns or roles as biomarkers in clinical practice[1][3][4].

Other names

PTGES3L-AARSD1Alanyl-tRNA editing protein Aarsd1AARSD1Alanyl-tRNA synthetase domain-containing protein 1PTGES3L-AARSD1 protein

None established; mechanisms for any hypothetical drug interactions are not described in current references[1][3].